by Richard Daverman, PhD
April 22, 2013 -- Syros Pharmaceuticals, a Boston area startup, raised $30 million to develop treatments for cancer and other diseases by controlling the switches that regulate gene expression. The WuXi PharmaTech Corporate Venture Fund participated in the funding, which was led by ARCH Venture Partners and Flagship Ventures. More details....
Stock Symbol: (NYSE: WX)
